Covid-19 roundup: As­traZeneca vac­cine halt­ed in Ger­many for be­low-60 pop­u­la­tion; Pfiz­er says Covid-19 vac­cine has 100% ef­fi­ca­cy in chil­dren ages 12-15

Ger­many will stop us­ing As­traZeneca’s Covid-19 vac­cine on res­i­dents be­low the age of 60 due to con­cerns sur­round­ing “rare but fa­tal blood clots,” ac­cord­ing to the Wash­ing­ton Post.

Chan­cel­lor An­gela Merkel said Tues­day that the gov­ern­ment can­not ig­nore the rec­om­men­da­tion from Ger­many’s vac­cine com­mit­tee. The Paul Ehrlich In­sti­tute re­port­ed 31 cas­es of ve­nous throm­bo­sis, a brain clot that can lead to he­m­or­rhag­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.